Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 7/20 | 0.61 |
| ▸ | TRPA1 | O75762 | 9/20 | 0.41 |
| ▸ | METAP2 | P50579 | 1/20 | 0.37 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.36 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.36 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1583878 | 0.92 | MET (0.70) | METTRPA1TRPM8CYP11B2 | |
| SCHEMBL562093 | 0.83 | MET (0.47) | METTRPA1 | |
| SCHEMBL12722326 | 0.81 | MET (0.85) | METTRPA1CHEK1CYP11B2 | |
| SCHEMBL12722397 | 0.77 | MET (0.46) | METCDC42BPAPBKSRPK1 | |
| SCHEMBL1583297 | 0.76 | MET (1.00) | METCHEK1CYP11B2 | |
| SCHEMBL1583928 | 0.73 | MET (1.00) | METTRPA1TRPM8 | |
| SCHEMBL1583681 | 0.72 | MET (0.53) | METCDC42BPAPBKSRPK1 | |
| SCHEMBL15501117 | 0.72 | MET (0.84) | METCDC42BPAPBKSRPK1CHEK1 | |
| SCHEMBL1077257 | 0.71 | MET (0.63) | METCDC42BPAPBKSRPK1CYP11B2 | |
| SCHEMBL182356 | 0.69 | MET (0.53) | METCDC42BPAPBKSRPK1CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9422263-B2 | Fluoro-substituted 3,5-dicyano-4-(1H-indazol-5-yl)-2,6-dimethyl-1,4-dihydropyridine derivatives and methods of use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-08-23 | — | — | US | disclosed |
| US-9422263-B2 | Fluoro-substituted 3,5-dicyano-4-(1H-indazol-5-yl)-2,6-dimethyl-1,4-dihydropyridine derivatives and methods of use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-08-23 | — | — | US | disclosed |
| EP-2485726-B1 | FLUORO-SUBSTITUTED 3,5-DICYANO-4-(1H-INDAZOL-5-YL)-2,6-DIMETHYL-1,4-DIHYDROPYRIDINE DERIVATIVES AND METHODS OF USE THEREOF | BAYER IP GMBH (DE) | 2014-03-12 | — | — | EP | disclosed |
| EP-2485726-B1 | FLUORO-SUBSTITUTED 3,5-DICYANO-4-(1H-INDAZOL-5-YL)-2,6-DIMETHYL-1,4-DIHYDROPYRIDINE DERIVATIVES AND METHODS OF USE THEREOF | BAYER IP GMBH (DE) | 2014-03-12 | — | — | EP | disclosed |
| US-20120264785-A1 | Fluoro-substituted 3,5-dicyano-4-(1H-indazol-5-yl)-2,6-dimethyl-1,4-dihydropyridine derivatives and methods of use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-10-18 | — | — | US | disclosed |
| US-20120264785-A1 | Fluoro-substituted 3,5-dicyano-4-(1H-indazol-5-yl)-2,6-dimethyl-1,4-dihydropyridine derivatives and methods of use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-10-18 | — | — | US | disclosed |
| WO-2011042368-A1 | FLUORO-SUBSTITUTED 3,5-DICYANO-4-(1H-INDAZOL-5-YL)-2,6-DIMETHYL-1,4-DIHYDROPYRIDINE DERIVATIVES AND METHODS OF USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264785-A1 | Fluoro-substituted 3,5-dicyano-4-(1H-indazol-5-yl)-2,6-dimethyl-1,4-dihydropyridine derivatives and methods of use thereof | MET, DCK, RET | MET 1/4885TRPA1 3933/4885METAP2 208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.